Lowell G H, Kaminski R W, Grate S, Hunt R E, Charney C, Zimmer S, Colleton C
Division of Pathology, Walter Reed Army Institute of Research, Washington, DC 20307, USA.
Infect Immun. 1996 May;64(5):1706-13. doi: 10.1128/iai.64.5.1706-1713.1996.
Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphylococcal enterotoxin B (SEB) toxoid in saline elicited higher anti-SEB serum immunoglobulin G (IgG) titers when the toxoid was formulated with proteosomes. In addition, intranasal immunization of mice with this proteosome-toxoid vaccine elicited high levels of anti-SEB IgA in lung and intestinal secretions, whereas the toxoid without proteosomes did not. Two i.m. immunizations with proteosome-toxoid plus alum also induced higher murine serum responses than alum-adjuvanted toxoid without proteosomes. Furthermore, proteosome-toxoid delivered intranasally in saline or i.m. with either saline or alum afforded significant protection against lethal SEB challenge in two D-galactosamine-sensitized murine models of SEB intoxication, i.e., the previously described i.m. challenge model and a new respiratory challenge model of mucosal SEB exposure. Efficacy correlated with the induction of high serum levels of anti-SEB IgG. In contrast, intranasal or i.m. immunization with toxoid in saline without proteosomes was not significantly protective in either challenge model. Proteosome-toxoid plus alum given i.m. also elicited more significant protection against respiratory challenge than the alum-adjuvanted toxoid alone. The capacity of proteosomes to enhance both i.m. and intranasal immunogenicity and efficacy of SEB toxoid indicates that testing such proteosome-SEB toxoid vaccines in the nonhuman primate aerosol challenge model of SEB intoxication prior to immunogenicity trials in humans is warranted. These data expand the applicability of the proteosome mucosal vaccine delivery system to protein toxoids and suggest that respiratory delivery of proteosome vaccines may be practical for enhancement of both mucosal and systemic immunity against toxic or infectious diseases.
用福尔马林处理的葡萄球菌肠毒素B(SEB)类毒素在盐水中对小鼠进行鼻内或肌内免疫以及对兔子进行肌内免疫时,当类毒素与蛋白酶体配制在一起时,可诱导产生更高的抗SEB血清免疫球蛋白G(IgG)滴度。此外,用这种蛋白酶体 - 类毒素疫苗对小鼠进行鼻内免疫可在肺和肠道分泌物中诱导产生高水平的抗SEB IgA,而不含蛋白酶体的类毒素则不能。用蛋白酶体 - 类毒素加明矾进行两次肌内免疫也比不含蛋白酶体的明矾佐剂类毒素诱导更高的小鼠血清反应。此外,在两种D - 半乳糖胺致敏的SEB中毒小鼠模型中,即先前描述的肌内攻击模型和新的黏膜SEB暴露呼吸道攻击模型中,盐水中鼻内递送或肌内递送(无论使用盐水还是明矾)的蛋白酶体 - 类毒素都能提供对致死性SEB攻击的显著保护作用。疗效与抗SEB IgG高血清水平的诱导相关。相比之下,在任何一种攻击模型中,用不含蛋白酶体的盐水中的类毒素进行鼻内或肌内免疫都没有显著保护作用。肌内注射蛋白酶体 - 类毒素加明矾也比单独使用明矾佐剂类毒素对呼吸道攻击产生更显著的保护作用。蛋白酶体增强SEB类毒素的肌内和鼻内免疫原性及疗效的能力表明,在对人类进行免疫原性试验之前,在非人类灵长类动物SEB中毒气溶胶攻击模型中测试这种蛋白酶体 - SEB类毒素疫苗是有必要的。这些数据扩展了蛋白酶体黏膜疫苗递送系统对蛋白质类毒素的适用性,并表明蛋白酶体疫苗的呼吸道递送对于增强针对毒性或感染性疾病的黏膜和全身免疫可能是可行的。